Stay updated on Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.

Latest updates to the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page
- CheckyesterdayChange DetectedThe page footer now shows Revision: v3.5.5 instead of v3.5.4. This indicates a small version update to the site's template or code.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision tag updated from v3.5.3 to v3.5.4 on the page. This indicates a minor internal update to the entry without altering study details or displayed information.SummaryDifference0.1%

- Check36 days agoChange DetectedRevision updated from v3.5.2 to v3.5.3, indicating a minor update to the page's revision history for this study record on ClinicalTrials.gov.SummaryDifference0.1%

- Check51 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check79 days agoChange DetectedRevision metadata updated: added v3.5.0 and removed v3.4.3.SummaryDifference0.1%

- Check86 days agoChange DetectedThe page now shows Revision: v3.4.3, replacing the prior v3.4.2.SummaryDifference0.1%

Stay in the know with updates to Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.